Floatz logo

Sacituzumab Tirumotecan

Small Cell Lung Carcinoma

Sichuan Universityantibody_drug_conjugatePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

276 Active assets in the Small Cell Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
Anti-Pd-L1 Monoclonal Antibody Shr-1316
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Berzosertib
National Cancer Institute (NCI)
Phase 2BBB
Cis-Diamminedichloroplatinum Ii
National Cancer Institute (NCI)
Phase 4BBB
Etoposide
Sichuan University
Phase 4BBB

View all 50 →

Same molecule, other indications

Sacituzumab Tirumotecan is also rated in:

non-small cell lung carcinomaActive
B
Indicative · Phase 3
63 / 100
View asset →
triple-negative breast carcinomaActive
B
Indicative · Phase 3
60 / 100
View asset →
breast cancerActive
B
Indicative · Phase 3
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →